SYMBIOCELLTECH Trademark

Trademark Overview

On Wednesday, February 1, 2017, a trademark application was filed for SYMBIOCELLTECH with the United States Patent and Trademark Office. The USPTO has given the SYMBIOCELLTECH trademark a serial number of 87320843. The federal status of this trademark filing is SECTION 8 & 15 - ACCEPTED AND ACKNOWLEDGED as of Wednesday, January 24, 2024. This trademark is owned by SymbioCell Tech, LLC. The SYMBIOCELLTECH trademark is filed in the Pharmaceutical Products category with the following description:

Cell-based therapeutic preparations for diabetes, neurodegenerative diseases, muscular dystrophy and autoimmune endocrine disorders
symbiocelltech

General Information

Serial Number87320843
Word MarkSYMBIOCELLTECH
Filing DateWednesday, February 1, 2017
Status702 - SECTION 8 & 15 - ACCEPTED AND ACKNOWLEDGED
Status DateWednesday, January 24, 2024
Registration Number5525659
Registration DateTuesday, July 24, 2018
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 12, 2017

Trademark Statements

Goods and ServicesCell-based therapeutic preparations for diabetes, neurodegenerative diseases, muscular dystrophy and autoimmune endocrine disorders

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, February 6, 2017
Primary Code005
First Use Anywhere DateTuesday, May 30, 2017
First Use In Commerce DateTuesday, May 30, 2017

Trademark Owner History

Party NameSymbioCell Tech, LLC
Party Type30 - Original Registrant
Legal Entity Type16 - Limited Liability Company
AddressSalt Lake City, UT 84108
Party NameSymbioCell Tech, LLC
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressSalt Lake City, UT 84108
Party NameSymbioCell Tech, LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressSalt Lake City, UT 84108

Trademark Events

Event DateEvent Description
Wednesday, January 24, 2024NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Wednesday, January 24, 2024REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Wednesday, January 24, 2024CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Tuesday, August 1, 2023TEAS SECTION 8 & 15 RECEIVED
Monday, July 24, 2023COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Tuesday, July 24, 2018REGISTERED-PRINCIPAL REGISTER
Tuesday, June 19, 2018NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Monday, June 18, 2018ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Wednesday, June 13, 2018STATEMENT OF USE PROCESSING COMPLETE
Thursday, May 24, 2018USE AMENDMENT FILED
Wednesday, June 13, 2018CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, May 24, 2018TEAS STATEMENT OF USE RECEIVED
Tuesday, February 6, 2018NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, December 12, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, December 12, 2017PUBLISHED FOR OPPOSITION
Wednesday, November 22, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, November 6, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, October 25, 2017TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, October 25, 2017CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, October 25, 2017ASSIGNED TO LIE
Thursday, October 12, 2017TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, April 28, 2017NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, April 28, 2017NON-FINAL ACTION E-MAILED
Friday, April 28, 2017NON-FINAL ACTION WRITTEN
Thursday, April 27, 2017ASSIGNED TO EXAMINER
Monday, February 6, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, February 4, 2017NEW APPLICATION ENTERED

Related Keywords

symbiocelltech dystrophy muscular autoimmune endocrine disorders diseases neurodegenerative based therapeutic preparations